{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:58:26Z","timestamp":1781179106883,"version":"3.54.1"},"reference-count":21,"publisher":"Scientific Scholar","issue":"02","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["South Asian J Cancer"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The widespread use of oxaliplatin plus infusional 5-fluorouracil (5-FU) and folinic acid (FOLFOX) in advanced gastric cancers is mainly based on clinical trials conducted at Western\/European countries. The prospective data on efficacy and safety of FOLFOX in advanced gastric cancer is lacking from the developing countries. In this prospective observational study, we evaluated the efficacy and toxicity of mFOLFOX-6 in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinomas, as first-line palliative chemotherapy.<\/jats:p>\n                  <jats:p>Patients with previously untreated metastatic adenocarcinoma of stomach\/GEJ, received mFOLFOX-6 (2\u2009hours infusion of oxaliplatin [85\u2009mg\/m2] and folinic acid [400\u2009mg\/m2], followed by fluorouracil 400\u2009mg\/m2 intravenous push, then a 46-hour continuous infusion of 5-FU [2,400\u2009mg\/m2]). Cycles were repeated every 2 weeks. The patients were prospectively followed up for response rates and toxicity.<\/jats:p>\n                  <jats:p>Sixty-six patients were included in the study with a median age of 57 years. Sixty-two patients were evaluable for response. The overall response rate was 53%, with a disease control rate (overall response and stable disease) of 81.8%. The median progression-free survival was 6 months (95% confidence interval [CI] 5.2\u20136.7 months) and the median overall survival was 11.5 months (95% CI 9.0\u201313.9 months). Ascites at presentation and more than one site of metastasis are associated with significantly lower survival on the log-rank test. Gastrointestinal and hematological toxicities were predominant, with rates of grade 3 to 4 nausea\/vomiting (13.6%), anemia (15.1%), and neutropenia (13.6%). Among other toxicities, neurosensory toxicities were common. Four (6%) patients had grade 3 peripheral neuropathy.<\/jats:p>\n                  <jats:p>mFOLFOX-6 is an active and well-tolerated chemotherapy regimen in advanced adenocarcinoma of stomach\/GEJ. This regimen has similar response rates and treatment outcomes with lesser grade 3 or 4 toxicities than that of triplet regimens compared to historical studies.<\/jats:p>","DOI":"10.1055\/s-0044-1788581","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T19:15:40Z","timestamp":1721675740000},"page":"271-276","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of mFOLFOX-6 in Advanced Gastric Cancer: A Prospective Observational Study"],"prefix":"10.25259","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7066-0173","authenticated-orcid":false,"given":"Amrith B.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3590-3261","authenticated-orcid":false,"given":"Varun","family":"Goel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9083-7100","authenticated-orcid":false,"given":"Srujana","family":"Joga","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3968-8354","authenticated-orcid":false,"given":"V.P.B.","family":"Koyyala","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India"},{"name":"Department of Medical Oncology, Assam Cancer Trust Hospital, Tejpur, Assam, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh C.","family":"Doval","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3306-9824","authenticated-orcid":false,"given":"Ullas","family":"Batra","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9149-6969","authenticated-orcid":false,"given":"Vineet","family":"Talwar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"issue":"03","key":"ref1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"01","key":"ref2","first-page":"7","article-title":"Cancer statistics, 2000","volume":"50","author":"R T Greenlee","year":"2000","journal-title":"CA Cancer J Clin"},{"issue":"08","key":"ref3","first-page":"CD004064","article-title":"Chemotherapy for advanced gastric cancer","volume":"8","author":"A D Wagner","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"18","key":"ref4","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","article-title":"Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data","volume":"24","author":"A D Wagner","year":"2006","journal-title":"J Clin Oncol"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.5009\/gnl.2013.7.4.385","article-title":"Chemotherapy for advanced gastric cancer: review and update of current practices","volume":"7","author":"S C Park","year":"2013","journal-title":"Gut Liver"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Y J Bang","year":"2010","journal-title":"Lancet"},{"issue":"25","key":"ref7","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"K Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Y Y Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"H Wilke","year":"2014","journal-title":"Lancet Oncol"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/jnci\/82.12.1046","article-title":"Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate","volume":"82","author":"J P Caussanel","year":"1990","journal-title":"J Natl Cancer Inst"},{"issue":"09","key":"ref11","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/sj.bjc.6602573","article-title":"A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients","volume":"92","author":"F De Vita","year":"2005","journal-title":"Br J Cancer"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10120-012-0204-z","article-title":"A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases","volume":"16","author":"V Catalano","year":"2013","journal-title":"Gastric Cancer"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.2004.07.042","article-title":"Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer","volume":"22","author":"S E Al-Batran","year":"2004","journal-title":"J Clin Oncol"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/annonc\/mdh422","article-title":"Palliative chemotherapy for advanced gastric cancer","volume":"15","author":"S S W\u00f6hrer","year":"2004","journal-title":"Ann Oncol"},{"issue":"23","key":"ref15","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1200\/JCO.2002.02.021","article-title":"Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients","volume":"20","author":"C Louvet","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1471-2407-8-148","article-title":"Modified FOLFOX-6 chemotherapy in advanced gastric cancer: results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker","volume":"8","author":"B Keam","year":"2008","journal-title":"BMC Cancer"},{"issue":"09","key":"ref17","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"26","author":"S E Al-Batran","year":"2008","journal-title":"J Clin Oncol"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"460","DOI":"10.4103\/0019-509X.92280","article-title":"FOLFOX (oxaliplatin and 5 fluorouracil\/leucovorin) in patients with untreated metastatic gastric adenocarcinoma phase II study","volume":"48","author":"H A Mohammad","year":"2011","journal-title":"Indian J Cancer"},{"issue":"20","key":"ref19","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.12998\/wjcc.v7.i20.3247","article-title":"Prognostic significance of malignant ascites in gastric cancer patients with peritoneal metastasis: a systemic review and meta-analysis","volume":"7","author":"L N Zheng","year":"2019","journal-title":"World J Clin Cases"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/jco.2004.22.90140.3621","article-title":"N9741: FOLFOX (oxaliplatin(Oxal)\/ 5-fluorouracil (5-FU)\/ leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU\/LV) in advanced colorectal cancer (CRC): final efficacy data from an intergroup study","volume":"22","author":"R M Goldberg","year":"2004","journal-title":"JCO"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1758835918780140","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: a review","volume":"10","author":"J D Sara","year":"2018","journal-title":"Ther Adv Med Oncol"}],"container-title":["South Asian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1788581.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:13:05Z","timestamp":1781176385000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.sajc.org\/efficacy-and-safety-of-mfolfox-6-in-advanced-gastric-cancer-a-prospective-observational-study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":21,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2025,12,18]]},"published-print":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1788581","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2278-330X","2278-4306"],"issn-type":[{"value":"2278-330X","type":"print"},{"value":"2278-4306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]}}}